CN102498099B - 可用于治疗糖尿病的hsl抑制剂 - Google Patents
可用于治疗糖尿病的hsl抑制剂 Download PDFInfo
- Publication number
- CN102498099B CN102498099B CN201080039803.8A CN201080039803A CN102498099B CN 102498099 B CN102498099 B CN 102498099B CN 201080039803 A CN201080039803 A CN 201080039803A CN 102498099 B CN102498099 B CN 102498099B
- Authority
- CN
- China
- Prior art keywords
- piperidine
- phenyl
- carboxylic acid
- amide
- sulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)c1ccc(*(C)C(C(CCC2)CC*2C(CC2CC2)=O)=O)cc1 Chemical compound CC(C)c1ccc(*(C)C(C(CCC2)CC*2C(CC2CC2)=O)=O)cc1 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170071 | 2009-09-11 | ||
| EP09170071.6 | 2009-09-11 | ||
| PCT/EP2010/063078 WO2011029808A1 (en) | 2009-09-11 | 2010-09-07 | Hsl inhibitors useful in the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102498099A CN102498099A (zh) | 2012-06-13 |
| CN102498099B true CN102498099B (zh) | 2014-10-29 |
Family
ID=42983383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080039803.8A Expired - Fee Related CN102498099B (zh) | 2009-09-11 | 2010-09-07 | 可用于治疗糖尿病的hsl抑制剂 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8258158B2 (enExample) |
| EP (1) | EP2475644B1 (enExample) |
| JP (1) | JP5642793B2 (enExample) |
| KR (1) | KR101369551B1 (enExample) |
| CN (1) | CN102498099B (enExample) |
| AR (1) | AR078351A1 (enExample) |
| AU (1) | AU2010294326A1 (enExample) |
| BR (1) | BR112012005140A2 (enExample) |
| CA (1) | CA2771452A1 (enExample) |
| ES (1) | ES2445166T3 (enExample) |
| IL (1) | IL217966A0 (enExample) |
| IN (1) | IN2012DN01232A (enExample) |
| MX (1) | MX2012002597A (enExample) |
| SG (1) | SG179031A1 (enExample) |
| TW (1) | TW201114744A (enExample) |
| WO (1) | WO2011029808A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2600739C2 (ru) | 2011-03-18 | 2016-10-27 | Байер Интеллектчуал Проперти Гмбх | N-(3-карбамоилфенил)-1н-пиразол-5-карбоксамидные производные и их применение для борьбы с животными-вредителями |
| EP2892888B1 (en) | 2012-09-10 | 2018-04-18 | Boehringer Ingelheim International GmbH | N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof |
| CN110325527B (zh) * | 2016-12-09 | 2022-08-09 | 勃林格殷格翰国际有限公司 | 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺 |
| GB2560713A (en) * | 2017-03-20 | 2018-09-26 | Eternygen Gmbh | Inhibitor of citrate transporter |
| CN110003176B (zh) * | 2019-05-28 | 2021-12-21 | 沈阳药科大学 | 含有酰胺的苯并咪唑类化合物及其应用 |
| CN110003177B (zh) * | 2019-05-28 | 2021-11-19 | 沈阳药科大学 | 含有脲基的苯并咪唑类化合物及应用 |
| GB201918410D0 (en) | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
| WO2022130352A1 (en) * | 2020-12-19 | 2022-06-23 | Cadila Healthcare Limited | Novel compounds suitable for the treatment of dyslipidemia |
| GB202108523D0 (en) | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compositions and their use for the treatment of alpha1-antitrypsin deficiency |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3779339B2 (ja) | 1994-03-04 | 2006-05-24 | 三井化学株式会社 | 含フッ素カルボン酸エステル化合物、液晶材料、液晶組成物および液晶素子 |
| WO1999065867A1 (en) * | 1998-06-17 | 1999-12-23 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| AR037352A1 (es) | 2001-11-14 | 2004-11-03 | Schering Corp | Compuestos ligandos de los receptores de los cannabinoides, una composicion farmaceutica , y el uso de dichos compuestos para la manufactura de medicamentos |
| EP1866285A1 (en) * | 2005-03-03 | 2007-12-19 | F. Hoffmann-Roche AG | 1-sulfonyl-piperdine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus |
| US8003662B2 (en) * | 2006-01-30 | 2011-08-23 | Array Biopharma, Inc. | Heterobicyclic thiophene compounds and methods of use |
| WO2007144394A2 (en) * | 2006-06-16 | 2007-12-21 | High Point Pharmaceuticals, Llc. | Pharmaceutical use of substituted piperidine carboxamides |
| EP1958631A1 (en) | 2007-02-14 | 2008-08-20 | AEterna Zentaris GmbH | Novel triazole derivatives as ligands of G-protein coupled receptors |
| US8324250B2 (en) * | 2009-03-19 | 2012-12-04 | Hoffmann-La Roche Inc. | Piperidine derivatives as NK3 receptor antagonists |
| US8329904B2 (en) * | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US8399676B2 (en) * | 2009-07-30 | 2013-03-19 | Hoffman-La Roche Inc. | Piperidine derivatives |
-
2010
- 2010-09-03 US US12/875,446 patent/US8258158B2/en not_active Expired - Fee Related
- 2010-09-07 KR KR1020127009254A patent/KR101369551B1/ko not_active Expired - Fee Related
- 2010-09-07 WO PCT/EP2010/063078 patent/WO2011029808A1/en not_active Ceased
- 2010-09-07 SG SG2012016085A patent/SG179031A1/en unknown
- 2010-09-07 IN IN1232DEN2012 patent/IN2012DN01232A/en unknown
- 2010-09-07 AU AU2010294326A patent/AU2010294326A1/en not_active Abandoned
- 2010-09-07 CA CA2771452A patent/CA2771452A1/en not_active Abandoned
- 2010-09-07 JP JP2012528339A patent/JP5642793B2/ja not_active Expired - Fee Related
- 2010-09-07 EP EP10751931.6A patent/EP2475644B1/en not_active Not-in-force
- 2010-09-07 CN CN201080039803.8A patent/CN102498099B/zh not_active Expired - Fee Related
- 2010-09-07 ES ES10751931.6T patent/ES2445166T3/es active Active
- 2010-09-07 MX MX2012002597A patent/MX2012002597A/es active IP Right Grant
- 2010-09-07 BR BR112012005140A patent/BR112012005140A2/pt not_active Application Discontinuation
- 2010-09-08 TW TW099130350A patent/TW201114744A/zh unknown
- 2010-09-09 AR ARP100103302A patent/AR078351A1/es unknown
-
2012
- 2012-02-06 IL IL217966A patent/IL217966A0/en unknown
Non-Patent Citations (1)
| Title |
|---|
| RN 1015382-66-7 REGISTRY;-;《STN》;20080417 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US8258158B2 (en) | 2012-09-04 |
| BR112012005140A2 (pt) | 2016-05-03 |
| EP2475644B1 (en) | 2014-01-08 |
| IN2012DN01232A (enExample) | 2015-05-15 |
| WO2011029808A1 (en) | 2011-03-17 |
| US20110065707A1 (en) | 2011-03-17 |
| EP2475644A1 (en) | 2012-07-18 |
| ES2445166T3 (es) | 2014-02-28 |
| IL217966A0 (en) | 2012-03-29 |
| TW201114744A (en) | 2011-05-01 |
| CN102498099A (zh) | 2012-06-13 |
| HK1169993A1 (en) | 2013-02-15 |
| KR20120059617A (ko) | 2012-06-08 |
| AR078351A1 (es) | 2011-11-02 |
| JP5642793B2 (ja) | 2014-12-17 |
| KR101369551B1 (ko) | 2014-03-04 |
| JP2013504533A (ja) | 2013-02-07 |
| MX2012002597A (es) | 2012-04-02 |
| SG179031A1 (en) | 2012-04-27 |
| CA2771452A1 (en) | 2011-03-17 |
| AU2010294326A1 (en) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102498099A (zh) | 可用于治疗糖尿病的hsl抑制剂 | |
| JP7376556B2 (ja) | 心臓状態に対するピリミジンジオン化合物 | |
| CN102844316B (zh) | 作为hsl抑制剂的氮杂环螺衍生物 | |
| JP5313125B2 (ja) | スルホンアミド誘導体 | |
| CN102421777A (zh) | 作为hsl抑制剂的氮杂环螺衍生物 | |
| CN102858743A (zh) | 作为可用于治疗糖尿病的hsl抑制剂的螺环-稠合的环己烷衍生物 | |
| CN104922117A (zh) | 用于治疗月经前病症的β-内酰氨基链烷酸 | |
| US20160272617A1 (en) | Substituted phenylalanine derivatives | |
| CN102639533B (zh) | 氮杂环螺衍生物 | |
| WO2013019966A1 (en) | Aromatic bycyclic derivatives as cxcr4 receptor modulators | |
| CN103429569B (zh) | 氮杂螺环癸酮化合物 | |
| HK1169993B (en) | Hsl inhibitors useful in the treatment of diabetes | |
| JP5503000B2 (ja) | ピペリジン誘導体並びに肥満症、糖尿病、脂質異常症及びアテローム動脈硬化症を処置するためのその使用 | |
| JP5886282B2 (ja) | 新規なアザ環状化合物 | |
| AU2017258697B2 (en) | Piperidinyl derivatives | |
| CA3022231C (en) | Piperidinyl derivatives | |
| HK1176607B (en) | Azacyclic spiroderivatives as hsl inhibitors | |
| HK1191326B (en) | Azaspirodecanone compounds | |
| HK1168597A (en) | Azacyclic spiro derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1169993 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1169993 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141029 Termination date: 20180907 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |